Trials / Completed

CompletedNCT00060684

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

A Phase I Trial of BBR 2778 in Combination With Fludarabine, Dexamethasone and Rituximab in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 30 (planned)

Sponsor: CTI BioPharma · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.

Detailed description

The FND-R regimen is commonly used in the treatment of indolent Non-Hodgkin's lymphoma (NHL) and contains the chemotherapy agents mitoxantrone, fludarabine, dexamethasone (a steroid) and the monoclonal antibody rituximab. In this trial we are replacing mitoxantrone with pixantrone, an agent with a similar chemical structure (both agents are DNA intercalators). The trial is being run in patients with relapsed or refractory indolent NHL and aims to define the appropriate dose of pixantrone to be used in this combination, as well as to obtain data on pixantrone's safety and activity profile in combination with these drugs. This trial is expected to recruit up to 30 patients in the USA. Patients will be treated with the drug combination for up to eight months and then followed closely in the four-week period after the last administration. After that, patients will receive physician check-ups every three months.

Conditions

Interventions

Type	Name	Description
DRUG	Pixantrone (BBR 2778)
DRUG	fludarabine
DRUG	dexamethasone
DRUG	rituximab

Timeline

Start date: 2001-12-01
Primary completion: 2005-01-01
Completion: 2007-05-01
First posted: 2003-05-12
Last updated: 2015-01-19

Locations

4 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00060684. Inclusion in this directory is not an endorsement.